Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6SUK

Crystal structure of Neprilysin in complex with Omapatrilat.

Summary for 6SUK
Entry DOI10.2210/pdb6suk/pdb
Related6GID
DescriptorNeprilysin, ZINC ION, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (7 entities in total)
Functional Keywordsmetallopeptidase, neural endopeptidase, omapatrilat, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight81738.15
Authors
Cozier, G.E.,Acharya, K.R.,Sharma, U. (deposition date: 2019-09-15, release date: 2020-05-13, Last modification date: 2024-10-23)
Primary citationSharma, U.,Cozier, G.E.,Sturrock, E.D.,Acharya, K.R.
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.
J.Med.Chem., 63:5488-5500, 2020
Cited by
PubMed Abstract: Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin-angiotensin-aldosterone system, respectively. They play an important role in blood pressure regulation and reducing the risk of heart failure. Vasopeptidase inhibitors omapatrilat and sampatrilat possess dual activity against these enzymes by blocking the ACE-dependent conversion of angiotensin I to the potent vasoconstrictor angiotensin II while simultaneously halting the NEP-dependent degradation of vasodilator atrial natriuretic peptide. Here, we report crystal structures of omapatrilat, sampatrilat, and sampatrilat-ASP (a sampatrilat analogue) in complex with NEP at 1.75, 2.65, and 2.6 Å, respectively. A detailed analysis of these structures and the corresponding structures of ACE with these inhibitors has provided the molecular basis of dual inhibitor recognition involving the catalytic site in both enzymes. This new information will be very useful in the design of safer and more selective vasopeptidase inhibitors of NEP and ACE for effective treatment in hypertension and heart failure.
PubMed: 32337993
DOI: 10.1021/acs.jmedchem.0c00441
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.75 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon